Common Contracts
9 similar Underwriting Agreement contracts by Amer Sports, Inc., Codorus Valley Bancorp Inc, Cytokinetics Inc, others
Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • Amer Sports, Inc. • Apparel & other finishd prods of fabrics & similar matl
Amer Sports, Inc., an exempted company incorporated under the laws of the Cayman Islands with limited liability (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ · ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ · ] additional shares (the “Optional Shares”) of the Company’s ordinary shares, par value EUR 0.0300580119630888 per share (the “Ordinary Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are collectively called the “Shares.”
GeneDx Holdings Corp. Class A Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • January 30th, 2023 • GeneDx Holdings Corp. • Services-health services
GeneDx Holdings Corp., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to Jefferies LLC (the “Underwriter”) an aggregate of 328,571,429 shares (the “Firm Shares”) and, at the election of the Underwriter, up to 49,285,714 additional shares (the “Optional Shares”) of Class A Common Stock, par value $0.0001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriter elects to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Exscientia plc [●] American Depositary Shares, each representing one Ordinary Share, nominal value £0.0005 per share Underwriting AgreementUnderwriting Agreement • September 27th, 2021 • Exscientia LTD • Biological products, (no disgnostic substances) • New York
Exscientia plc, a public limited company incorporated under the laws of England and Wales with company number 13483814 (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”) and in the manner contemplated by this Agreement, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] American Depositary Shares (the “Firm ADSs”) representing [●] ordinary shares, nominal value £0.0005 per share (the “Ordinary Shares”) and, at the election of the Underwriters, up to [●] additional American Depositary Shares representing [●] Ordinary Shares (the “Optional ADSs”) of the Company (the Firm ADSs and the Optional ADSs that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “ADSs”).
Underwriting AgreementUnderwriting Agreement • March 15th, 2021 • Gain Therapeutics, Inc. • Pharmaceutical preparations • New York
Gain Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representatives (the “Representatives”), an aggregate of 3,636,364 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 545,454 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
MINISO Group Holding Limited [●] American Depositary Shares Representing [●] Class A Ordinary Shares (par value US$0.00001 per share) Underwriting AgreementUnderwriting Agreement • October 13th, 2020 • MINISO Group Holding LTD • Retail-variety stores • New York
MINISO Group Holding Limited, an exempted company incorporated in the Cayman Islands (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] American Depositary Shares, each representing four Class A ordinary shares, par value US$0.00001 per share (together with Class B ordinary shares of the Company, the “Ordinary Shares”), of the Company. At the election of the Representatives on behalf of the Underwriters, the Company also proposes to sell to the several Underwriters up to [●] additional American Depositary Shares of the Company (such [●] American Depositary Shares herein called the “Optional ADSs”). The Firm ADSs and the Optional ADSs that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “ADSs.”
Cytokinetics, Incorporated 7,291,667 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • July 17th, 2020 • Cytokinetics Inc • Pharmaceutical preparations • New York
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 7,291,667 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,093,750 additional shares (the “Optional Securities”) of common stock, par value $0.001 (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
1,519,000 Shares Codorus Valley Bancorp, Inc. Common Stock $2.50 par value per share Underwriting AgreementUnderwriting Agreement • December 10th, 2015 • Codorus Valley Bancorp Inc • Savings institution, federally chartered • New York
Codorus Valley Bancorp, Inc., a Pennsylvania corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Sandler O’Neill & Partners, L.P. (“Sandler O’Neill” or an “Underwriter”) and each of the other underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom Sandler O’Neill is acting as representative (in such capacity, the “Representative”) with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 1,519,000 shares of common stock, $2.50 par value per share, of the Company (the “Stock”), as set forth in Schedule I hereto (the “Firm Shares”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2 hereof to purchase all or any part of 227,850 additional shares of c
WESTERN ALLIANCE BANCORPORATION Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • August 24th, 2010 • Western Alliance Bancorporation • State commercial banks • New York
Western Alliance Bancorporation, a Nevada corporation (the “Company”), agrees, subject to the terms and conditions stated herein, to issue and sell to Keefe, Bruyette & Woods, Inc. (the “Underwriter”, “you” or “your”) an aggregate of 7,000,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”).
4,500,000 Shares Provident Financial Holdings, Inc. Common Stock $.01 Par Value Per Share Underwriting Agreement December 9, 2009Underwriting Agreement • December 10th, 2009 • Provident Financial Holdings Inc • Savings institution, federally chartered • New York
Provident Financial Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Sandler O’Neill & Partners, L.P. (“Sandler O’Neill” or an “Underwriter”) and each of the other underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom Sandler O’Neill is acting as representative (in such capacity, the “Representative”) with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 4,500,000 shares of common stock, $.01 par value per share, of the Company (the “Common Stock”), as set forth in Schedule I hereto (the “Firm Shares”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2 hereof to purchase all or any part of 675,000 additional sha
